Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma

Nancy L. Bartlett; Uwe Hahn; Won Seog Kim; Isabelle Fleury; Kamel Laribi; Juan Miguel Bergua; Krimo Bouabdallah; Nicholas Forward; Fontanet Bijou; David MacDonald; Craig A. Portell; Herve Ghesquieres; Grzegorz Nowakowski; Christopher A. Yasenchak; Monica Patterson; Linda Ho; Evelyn Rustia; Michelle Fanale; Fei Jie; Jeong A. Kim

doi:10.1080/14796694.2025.2513219

Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma

Nancy L. Bartlett, Uwe Hahn, Won Seog Kim, Isabelle Fleury, Kamel Laribi, Juan Miguel Bergua, Krimo Bouabdallah, Nicholas Forward, Fontanet Bijou, David MacDonald, Craig A. Portell, Herve Ghesquieres, Grzegorz Nowakowski, Christopher A. Yasenchak, Monica Patterson, Linda Ho, Evelyn Rustia, Michelle Fanale, Fei Jie, Jeong A. Kim

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1965-1983
Number of pages	19
Journal	Future Oncology
Volume	21
Issue number	16
DOIs	https://doi.org/10.1080/14796694.2025.2513219
State	Published - 2025
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/14796694.2025.2513219

Cite this

Bartlett, N. L., Hahn, U., Kim, W. S., Fleury, I., Laribi, K., Bergua, J. M., Bouabdallah, K., Forward, N., Bijou, F., MacDonald, D., Portell, C. A., Ghesquieres, H., Nowakowski, G., Yasenchak, C. A., Patterson, M., Ho, L., Rustia, E., Fanale, M., Jie, F., & Kim, J. A. (2025). Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma. Future Oncology, 21(16), 1965-1983. https://doi.org/10.1080/14796694.2025.2513219

@article{95be2c0b117542c68f72d6163f7e7e95,

title = "Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma",

author = "Bartlett, \{Nancy L.\} and Uwe Hahn and Kim, \{Won Seog\} and Isabelle Fleury and Kamel Laribi and Bergua, \{Juan Miguel\} and Krimo Bouabdallah and Nicholas Forward and Fontanet Bijou and David MacDonald and Portell, \{Craig A.\} and Herve Ghesquieres and Grzegorz Nowakowski and Yasenchak, \{Christopher A.\} and Monica Patterson and Linda Ho and Evelyn Rustia and Michelle Fanale and Fei Jie and Kim, \{Jeong A.\}",

year = "2025",

doi = "10.1080/14796694.2025.2513219",

language = "English",

volume = "21",

pages = "1965--1983",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "16",

}

Bartlett, NL, Hahn, U, Kim, WS, Fleury, I, Laribi, K, Bergua, JM, Bouabdallah, K, Forward, N, Bijou, F, MacDonald, D, Portell, CA, Ghesquieres, H, Nowakowski, G, Yasenchak, CA, Patterson, M, Ho, L, Rustia, E, Fanale, M, Jie, F & Kim, JA 2025, 'Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma', Future Oncology, vol. 21, no. 16, pp. 1965-1983. https://doi.org/10.1080/14796694.2025.2513219

TY - JOUR

T1 - Plain language summary of the ECHELON-3 study

T2 - brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma

AU - Bartlett, Nancy L.

AU - Hahn, Uwe

AU - Kim, Won Seog

AU - Fleury, Isabelle

AU - Laribi, Kamel

AU - Bergua, Juan Miguel

AU - Bouabdallah, Krimo

AU - Forward, Nicholas

AU - Bijou, Fontanet

AU - MacDonald, David

AU - Portell, Craig A.

AU - Ghesquieres, Herve

AU - Nowakowski, Grzegorz

AU - Yasenchak, Christopher A.

AU - Patterson, Monica

AU - Ho, Linda

AU - Rustia, Evelyn

AU - Fanale, Michelle

AU - Jie, Fei

AU - Kim, Jeong A.

PY - 2025

Y1 - 2025

UR - https://www.scopus.com/pages/publications/105009523631

U2 - 10.1080/14796694.2025.2513219

DO - 10.1080/14796694.2025.2513219

M3 - Article

C2 - 40536327

AN - SCOPUS:105009523631

SN - 1479-6694

VL - 21

SP - 1965

EP - 1983

JO - Future Oncology

JF - Future Oncology

IS - 16

ER -

Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma

UN SDGs

Access to Document

Other files and links

Cite this